Detecting and Excluding COVID-19 at Point of Need

  • Funded by Foreign, Commonwealth & Development Office (FCDO), Wellcome Trust
  • Total publications:11 publications

Grant number: 220764/Z/20/Z

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2021
  • Known Financial Commitments (USD)

    $1,163,416.24
  • Funder

    Foreign, Commonwealth & Development Office (FCDO), Wellcome Trust
  • Principle Investigator

    Pending
  • Research Location

    United Kingdom, Europe
  • Lead Research Institution

    Mologic
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Diagnostics

  • Special Interest Tags

    Gender

  • Study Subject

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Rapid diagnostics have been identified by the WHO R&D Blueprint as a critical unmet need for the control of COVID-19 - particularly in the absence of a vaccine and proven antiviral agents. Our primary objective is to develop a low cost, high performance rapid test for the detection and exclusion of SARS-CoV-2, the causative virus of coronavirus disease 2019 (COVID-19). The technology will be made available in line with the Global Access Policy for Gavi-eligible countries that are most vulnerable to onward transmission of COVID-19 and of limited detection due to insufficient laboratory capacity. The RDT will be appropriate for assembly and manufacture with multiple quality-assured partners to meet demand.

Publicationslinked via Europe PMC

Last Updated:39 minutes ago

View all publications at Europe PMC

A prospective diagnostic evaluation of accuracy of self-taken and healthcare worker-taken swabs for rapid COVID-19 testing.

SARS-CoV-2 enzyme-linked immunosorbent assays as proxies for plaque reduction neutralisation tests.

Twelve lateral flow immunoassays (LFAs) to detect SARS-CoV-2 antibodies.

Prevalence of neutralising antibodies against SARS-CoV-2 in acute infection and convalescence: A systematic review and meta-analysis.

Comparative evaluation of ten lateral flow immunoassays to detect SARS-CoV-2 antibodies

Immunoglobulin-G Enzyme-Linked Immunosorbent Assay Predicts Neutralising Antibody Response in Convalescent SARS-CoV-2 Patients

Self-sampling of capillary blood for serological testing of SARS-CoV-2 by COVID-19 IgG ELISA

Self-sampling of capillary blood for SARS-CoV-2 serology.

Dynamics of IgG seroconversion and pathophysiology of COVID-19 infections